S267: PROPERDIN-BLOCKING ANTIBODIES ATTENUATE COMPLEMENT ALTERNATIVE PATHWAY ACTIVATION TRIGGERED BY CELL-FREE HEME IN SICKLE CELL DISEASE MODELS

• T. Trovati Maciel,
• R. Cofiell,
• C. Carvalho,
• S. Allali,
• R. Rignault,
• A. Bennet,
• Y. Dai,
• P. Tamburini,
• C. Gasteyger,
• O. Hermine,
• S. K. Kim

Affiliations

T. Trovati Maciel

1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France

R. Cofiell

2 Translational Research, Alexion AstraZeneca Rare Disease, New Haven, CT

C. Carvalho

1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France

S. Allali

1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France

R. Rignault

1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France

A. Bennet

3 Clinical Development and Translational Sciences, Alexion AstraZeneca Rare Disease, Boston, MA

Y. Dai

3 Clinical Development and Translational Sciences, Alexion AstraZeneca Rare Disease, Boston, MA

P. Tamburini

4 Research, Alexion AstraZeneca Rare Disease, New Haven, CT, United States of America

C. Gasteyger

5 Clinical Development and Translational Sciences, Alexion AstraZeneca Rare Disease, Zurich, Switzerland

O. Hermine

1 Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm, Paris, France

S. K. Kim

2 Translational Research, Alexion AstraZeneca Rare Disease, New Haven, CT